Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Editorial Note

Editorial Notes are published by PLOS to provide readers information relevant to an article’s interpretation.

See all article types »

Editorial Note: The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease

  • The PLOS One Editors

After publication of this article [1], concerns were raised about the interpretation of Fig1B. Specifically, the fourth sentence of the Results sub-section titled AT2220 Stabilized rhGAA, Preventing Denaturation and Loss of Activity, reports a loss of GAA activity with a half-life of 3–4 hours in Fig 1B. However, upon editorial assessment the PLOS One Editors consider the data in Fig 1B to appear to be consistent with a GAA half-life of 13–14 hours.

Additionally, it is noted that the primary data underlying results in this article [1] are not included with the published article.

The authors did not respond to the journal’s communications.

The PLOS One Editors issue this Editorial Note to inform readers of the above discrepancy, which does not appear to affect the article’s main results and conclusions.

Reference

  1. 1. Khanna R, Flanagan JJ, Feng J, Soska R, Frascella M, Pellegrino LJ, et al. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS One. 2012;7(7):e40776. pmid:22815812

Citation: The PLOS One Editors (2025) Editorial Note: The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease. PLoS One 20(10): e0334975. https://doi.org/10.1371/journal.pone.0334975

Published: October 22, 2025

Copyright: © 2025 The PLOS One Editors. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.